Evidence map›Paper›PMID 30792887›Full record

SynthesisRMD open2019

Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials.

Bénédicte Champs, Yannick Degboé, Thomas Barnetche, Alain Cantagrel, Adeline Ruyssen-Witrand, Arnaud Constantin

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in RMD open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Inflammation and Heart Failure: Searching for the Enemy-Reaching the Entelechy.Journal of cardiovascular development and disease · 2023
    Review
  10. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Commentary: Systemic effects of IL-17 in inflammatory arthritis.Frontiers in cardiovascular medicine · 2019
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Bénédicte ChampsRhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France.
Yannick DegboéRhumatologie, Hôpital Pellegrin, Bordeaux Université, Bordeaux, France.
Thomas BarnetcheRhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France.
Alain CantagrelRhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France.
Adeline Ruyssen-WitrandRhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France.
Arnaud ConstantinRhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France.
Centre Hospitalier Universitaire de Toulouse · FRUniversité Toulouse III - Paul Sabatier · FRHôpital Pellegrin · FRHôpital Purpan · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy. Methods: Screening for the study was carried out using MEDLINE, Cochrane and Embase, from the inception of the database to December 2017. Randomised controlled trials (RCTs) of anti-tumour necrosis factor (TNF), anti-interleukin (IL)12/23, anti-IL23 and anti-IL17 agents for the treatment of PsA or psoriasis were included. Two investigators independently extracted MACEs or CHF data reported during the placebo-controlled phase. The primary outcome measures were the incidence of MACEs or CHF. Results: Of 753 references screened, 62 articles were selected, and 12 articles were added by manual searches. Accordingly 77 RCTs were included in the meta-analysis (MA) (10 174 patient-years (P-Y)). No significant difference was observed in MACE incidences in patients receiving anti-TNF, anti-IL12/23, anti-IL23 or anti-IL17 agents in comparison to the placebo. However, 10 MACEs were observed in the anti-IL12/23 group (1150 P-Y) compared with 1 in the placebo group (652 P-Y), with 0.01 -0.00 to 0.02 event/P-Y risk difference, which is not statistically significant. This trend was not observed in the anti-IL23 group. No significant difference was observed in CHF incidence in patients receiving biological agents in comparison to placebo. Conclusion: This MA of 77 RCTs did not reveal any significant change in the short-term risk of MACE or CHF in patients with PsA or psoriasis initiating a biological therapy.

Indexed as

Biological TherapyArthritis, PsoriaticHeart FailureHumansPsoriasisRandomized Controlled Trials as TopicTreatment Outcomebiological agentcongestive heart failuremajor cardiovascular eventpsoriasisPsoriatic arthritis

Identifiers

PMID30792887
PMCPMC6350717
OpenAlexW2913448064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.